TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
MedPage Today’s Nov. 1, 2026, roundup collected eight remarks from clinicians and researchers on developments in medicine and health policy. The comments span an American Diabetes Association report, clinical trial findings, exam software glitches, fertility technology, insurance reform and medication safety; the brief roundup does not provide full study or investigation details.
MedPage Today published eight medical and health-policy quotations on November 1, 2026, including criticism of an American Diabetes Association report, mixed trial findings and concerns about software problems affecting an internal medicine board exam. The roundup captures reactions from clinicians and researchers, but it is a brief selection of comments rather than a full account of the underlying studies or disputes.
The opening quotation came from Aaron Kelly, PhD, of the University of Minnesota, commenting on the American Diabetes Association’s final report concerning five scientists who were ousted from this year’s annual meeting. Kelly said, “They’re looking for scapegoats.” The roundup does not detail the report’s findings, the circumstances of the scientists’ removal or the association’s response to Kelly’s criticism.
Two comments addressed clinical research. Hugh Gallagher, MBBS, PhD, of Epsom and St Helier University Hospitals NHS Trust in England, said, “So 130 years later, we’re still trying to work out what to do with it,” after a trial found low-dose aspirin did not reduce major vascular events in adults with chronic kidney disease. Separately, Nathalie Gaspar, MD, PhD, of Gustave Roussy in France, described positive phase III results for an investigational osteosarcoma drug tested in adolescents and adults as “something we have not seen for years.”
The other comments covered a range of concerns and emerging approaches. Aaron Gans, MD, described receiving an “indeterminate” internal medicine board exam score following widespread software glitches and questioned whether a systemic data-collection error had occurred. Hemant Suryawanshi, PhD, discussed an AI-powered tool to detect extremely rare sperm in men with azoospermia. The roundup also included remarks on No Surprises Act reform, possible interactions between GLP-1 drugs and lithium, and SGLT2 inhibitors’ association with higher hemoglobin and hematocrit levels.
Research, Testing and Care Under Scrutiny
The comments point to issues with direct consequences for patients, medical professionals and research communities: whether a treatment changes clinical outcomes, how exam results are produced, and how emerging tools might affect diagnosis or care. The range of topics also shows why a quotation roundup can alert readers to developments beyond a single specialty.
However, the comments are not a substitute for the evidence behind each issue. In particular, the aspirin result concerns adults with chronic kidney disease and a specific outcome—major vascular events—while the osteosarcoma comment refers to positive phase III results without giving trial data. Study design, effect sizes and safety findings are needed to assess what either result means for clinical practice.
Products Worth Considering
Samsung 27-inch Odyssey G5 QHD Gaming Monitor (G51F)
Jackery HomePower 3600 Plus Portable Power Station, 3584Wh, 3600W
Bose QuietComfort Ultra Headphones (2nd Gen), Wireless Bluetooth Noise-Cancelling Over-Ear Headphones, Black
As an affiliate, we earn on qualifying purchases.
Eight Comments Across Medicine
MedPage Today describes the item as a weekly collection of quotations heard by its reporters. The November 1 edition brings together eight speakers and eight separate subjects, ranging from an association report and a testing problem to clinical trials and federal health-policy reform. The quotes are presented as reactions or summaries, not as a single connected investigation.
Some remarks refer to research at different stages. The osteosarcoma drug is described as investigational despite positive phase III results, and the AI-powered sperm-identification tool is presented as a designed technology. The roundup does not state that either has received regulatory approval or is routinely available. It likewise gives no detailed timeline for the board exam software issue or for proposed changes to the No Surprises Act.
““They’re looking for scapegoats.””
— Aaron Kelly, PhD, University of Minnesota
Details Behind the Quotes Remain Limited
The source is a short roundup and leaves key questions unanswered. It does not give the full ADA report, the basis for Kelly’s allegation, or the association’s response. It also does not identify the aspirin trial’s size, duration or other outcomes, or provide the osteosarcoma trial’s data, safety results or next regulatory steps.
For the exam issue, the roundup reports software glitches and Gans’s “indeterminate” result but does not say how many candidates were affected, whether scores were reviewed or whether a data-collection error was found. It also offers no performance or validation details for the sperm-identification tool, and no specific proposals or timetable for No Surprises Act reform. The remarks about GLP-1 drugs and lithium and SGLT2 inhibitors are not accompanied by study details, so their clinical implications cannot be determined from this item alone.
Follow the Studies and Reviews
The next useful updates would be the underlying trial reports and full study data, including details on the aspirin and osteosarcoma findings. Further reporting from the American Diabetes Association could clarify what its final report concluded and how it addressed the five scientists’ removal.
Information from exam administrators would be needed to establish the scale of the software problems and whether scores or data were corrected. For the policy and technology topics, readers would need specific reform proposals, tool-validation results and further evidence on the medication-related findings. The November 1 roundup itself does not announce deadlines or confirm any of those next steps.
Key Questions
What did MedPage Today publish?
It published a weekly roundup of eight quotations from medical professionals and researchers, covering clinical research, testing, technology and health policy.
What was the dispute behind the “scapegoats” comment?
Aaron Kelly was commenting on the American Diabetes Association’s final report concerning five scientists ousted from this year’s annual meeting. The roundup does not provide the report’s findings or the association’s response to Kelly.
What did the aspirin trial find?
As summarized in the roundup, low-dose aspirin did not reduce major vascular events in a trial of adults with chronic kidney disease. The item does not provide the trial’s size, duration or other results.
Were the osteosarcoma drug results confirmed in detail?
The roundup reports that phase III results for an investigational osteosarcoma drug were positive, based on Gaspar’s comment. It does not include the data, safety findings or regulatory status.
What remains unknown about the board exam software problems?
The roundup reports widespread software glitches and an “indeterminate” score for Aaron Gans, but does not say how many candidates were affected, whether results were reviewed or whether a systemic data error was confirmed.
Source: medpagetoday.com
